Amphastar Pharmaceuticals, Inc. (AMPH) FinancialsAMPHFinancialAmphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. (AMPH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Other finished pharmaceutical products, accounting for 19.0% of total sales, equivalent to $34.65M. Other significant revenue streams include Epinephrine and Glucagon. Understanding this composition is critical for investors evaluating how AMPH navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Amphastar Pharmaceuticals, Inc. maintains a gross margin of 50.83%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 21.60%, while the net margin is 16.50%. These profitability ratios, combined with a Return on Equity (ROE) of 10.30%, provide a clear picture of how effectively AMPH converts its operational activities into shareholder value.

In the context of the broader market, AMPH competes directly with industry leaders such as ANNX and ARDX. With a market capitalization of $930.73M, it holds a significant position in the sector. When comparing efficiency, AMPH's gross margin of 50.83% stands against ANNX's N/A and ARDX's 95.24%. Such benchmarking helps identify whether Amphastar Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Amphastar's total revenue has shown only a 3.2% annualized growth over the past two years, which is below its five-year trend. The gross margin is currently at 50.83%, but this is down from previous quarters, indicating potential profitability issues.